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Promoter hypermethylation mediates gene silencing in many neoplasms. Acute leukemia has been reported to harbor multiple genes 
aberrantly silenced by hypermethylation. Aim: In present study, we investigated the prevalence of hypermethylation of cas-
pase-8 (CASP8), TMS1 and DAPK genes in correlation with clinicopathological factors in childhood acute lymphoblastic leukemia 
(ALL). Materials and Methods: A case-control study has been conducted based on bone marrow and peripheral blood samples from 
125 ALL patients and 100 sex-age matched healthy controls. Methylation specific polymerase chain reaction (PCR) and bisulfite 
sequencing PCR was performed to analyze the methylation status of these genes. Reverse transcription PCR and real time PCR 
was carried out to determine changes in the mRNA expression level of the genes due to hypermethylation. Results: Hypermethylation 
of the 5´CpG islands of the CASP8, TMS1 and DAPK gene promoters was found in 3.2, 6.4, and 13.6% of 125 childhood ALL 
samples from north Indian population, respectively. There were significant differences in pattern of hypermethylation 
of TMS1 (p = 0.045) and DAPK (p < 0.001) between patients and healthy controls. Down-regulation of mRNA expression was 
found in cases in which CASP8, TMS1 and DAPK were hypermethylated. Conclusions: The present study indicated the impact 
of hypermethylation-mediated inactivation of CASP8, TMS1 and DAPK genes, which is associated with risk of childhood ALL. This 
abnormality occurs in leukemogenesis and it may be used as a biomarker and for predicting the prognosis of ALL.
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Childhood acute lymphoblastic leukemia (ALL), 
clinically known as heterogeneous disorder, is caused 
by uncontrolled proliferation of immature B or T lym-
phoblasts. It was estimated to be the seventh most 
prevalent type of cancer accounting for 3% of the 
new cancer cases and also accounts for the ninth rank 
in causes of death among children. Epigenetics can 
be described as a stable alteration in gene expression 
potential that takes place during development and cell 
proliferation, without any change in gene sequence. 
In higher eukaryotes, DNA is methylated only at cyto-
sines adjacent to guanosine in the CpG dinucleotide. 
This modification has important regulatory effects 
on gene expression, especially when involving CpG-
rich areas known as CpG islands (CGI) located in the 
promoter regions of many genes [1]. Hypermethy-
lation of the CGI of gene promoter of tumor suppressor 
genes is one of the earliest and most frequent altera-
tions leading to cancer. The specific patterns of CGI 
hypermethylation may provide a useful signature for 
tumor diagnosis and prognosis [2]. Aberrant promoter 
hypermethylation of tumor suppressor genes (without 
any structural alteration) and its association with trans-
criptional inactivation is considered as an epigenetic 
mechanism in leukemia pathogenesis [3–5].
Death-associated protein kinase 1 (DAPK) 
is a 160 kDa Ca2+/calmodulin dependent, cytoskeletal-
associated protein kinase. It has been found that DAPK 
exerts an apoptotic effect by inside-out inactivation 
of integrin, thereby suppressing the matrix survival 
signal and activating a p53-dependent apoptosis 
pathway [6, 7]. Several studies have suggested that 
loss of DAPK expression or methylation of CGI in DAPK 
promoter region may be characteristic of highly inva-
sive or metastatic tumors [8]. More than 100 reports 
from different laboratories were published on DAPK 
gene methylation in various human tumors. Also based 
on other report several B-cell lymphoma cell lines 
have decreased or absent expression of DAPK RNA 
or protein [9]. This finding suggests that abnormal loss 
of DAPK expression could be associated with aberrant 
promoter region methylation, serving as an alternative 
to the genetic loss of a tumor-suppressor gene func-
tion by deletion or mutation [10, 11].
TMS1 (target of methylation-mediated silencing, 
also known as ASC or PYCARD), is commonly silenced 
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by methylation in human cancer cells. TMS1 was identi-
fied in a screen for downstream targets of methy lation-
mediated gene silencing induced by overexpression 
of human DNA methyltransferase-1 [12]. Methylation 
pattern of TMS1 at the TMS1 locus as well as the ex-
pression of TMS1 in many cancer cell lines especially 
epithelial cancer cell lines has been shown by many re-
search groups [12–16]. TMS1-induced apoptosis could 
be blocked with a dominant-negative caspase-9, but 
not a dominant-negative caspase-8, which suggested 
that it was a part of intrinsic mitochondrial signaling [17].
Caspase-8 gene (CASP8) located at human chromo-
some 2q33-q34 [18] is involved in the regulation of apop-
tosis and also in several non-apoptotic processes such 
as proliferation, differentiation, and NF-kB activation [19]. 
Caspase-8 expression or function can be impaired 
in cancers by mutation, deletion, epigenetic silencing, 
alternative splicing or posttranscriptional mechanisms 
such as phosphorylation. A high methylation rate and 
thereby gene silencing for CASP8 in medulloblastoma 
has been reported recently [20, 21].
So, the aim of present study was to investigate the 
prevalence of hypermethylation of CASP8, TMS1 and 
DAPK in correlation with clinicopathological factors 
in childhood ALL. Our results indicate that hypermethy-
lation-mediated inactivation of caspase-8, TMS1 and 
DAPK is associated with the risk of childhood ALL and 
it could be used as a biomarker and prognostic marker 
in these patients.
MATERIALS AND METHODS
Sample collection. The bone marrow (BM) aspi-
rate was collected from patients admitted to Hema-
tology-Oncology ward, Advanced Pediatric Center, 
PGIMER, Chandigarh, India, at the time of initial 
diagnosis and prior to any treatment regimen. The 
study was approved by Institute Ethical Committee and 
informed consent was obtained from the guar dians 
of all the patients recruited in the study. Diagnosis 
was based on standard hematological protocol ac-
cording to WHO classification. For statistical analysis, 
children were grouped according to National Cancer 
Research Institute (NCRI) risk classification; the 
clinical characteristics of the leukemic patients and 
regional distribution among northern states of India 
are shown in Table 1 and 2, respectively. For controls, 
blood samples were obtained from healthy donors 
with respect to median and mean of sex and age 
of patients. Mononuclear cells were obtained from 
BM aspirate and blood samples by centrifugation 
on Ficoll-Histopaque (Sigma-Aldrich, St. Louis, Mis-
souri, USA) density gradient and were used for DNA 
and RNA extraction.
DNA isolation. DNA was extracted from mono-
nuclear cells of BM and blood using standard pro-
teinase K (Sigma-Aldrich, St. Louis, Missouri, USA) 
digestion followed by phenol chloroform extraction 
and ethanol precipitation. The DNA concentration was 
determined by spectrophotometry and its integrity was 
checked by 1.5% agarose gel electrophoresis.
Table 1. Demographic and clinical characteristics of study population
Patients (N = 125) Control group (N = 100)
n (%) n (%)
Gender
Male 97 (77.6) 77 (77.0)
Female 28 (22.4) 23 (23.0)
Mean age, years (± SD) 6.46 ± 3.34 6.55 ± 3.37
Age < 2 12 (9.6) 11 (11.0)
2 < age < 5 43 (34.4) 33 (33.0)
age > 5 70 (56.0) 56 (56.0)
Cell lineage
B-lineage ALL 118 (94.4) –
T-lineage ALL 7 (5.6) –
NCRI risk group
Standard 103 (82.4) –
High 22 (17.6) –
Table 2. Distribution of cases on the basis of regional distribution
State Patients (n = 125), %
Punjab 55
Haryana 34
Uttar Pradesh 16
Himachal Peradesh 10
Chandigarh 5
Jammu & Kashmir 5
Sodium bisulfite modification of DNA. Sodium 
bisulfite modification of genomic DNA was performed 
as described previously, with little modifications [1]. 
A sample of genomic DNA (2 µg) was denatured with 
NaOH (final concentration 0.2 M) followed by incubation 
at 37 °C for 10 min. Then, DNA was modified by incuba-
tion with 30 µl of 10 mM hydroquinone (Sigma-Aldrich, 
St. Louis, Missouri, USA). 520 µl of freshly prepared 
3 M sodium bisulfite (Sigma-Aldrich, St. Louis, Missouri, 
USA) (pH = 5) was added and the mixture was incubated 
at 50 ˚C for 16 h. After incubation, modified DNA was 
purified using DNA Wizard Clean-up (Promega, Madi-
son, Wisconsin, USA) according to manufacturer’s pro-
cedure and eluted into 50 µl of sterile water followed 
by desulfonation in 0.3 N NaOH at 25 °C for 5 min. De-
sulfonated DNA was then precipitated with ammonium 
acetate and ethanol, washed with 70% ethanol and 
re-suspended in 20 µl of sterile water.
Methylation specific polymerase chain reaction 
(MSP-PCR). MSP-PCR was used to study the meth-
ylation status of the CGI in promoter regions of CASP8, 
TMS1 and DAPK. The reaction mixture (50 µl) contained 
2 µl of above bisulfite-treated DNA, 0.2 mM of dNTP 
(each at concentration 10 mM) (Fermentas Life Sci-
ence, Waltham, Massachusetts, USA), 10 ρM of each 
primer (synthesized by Sigma), 5 µl of BSA (10 mg/ml) 
(Sigma-Aldrich, St. Louis, Missouri, USA), 10X PCR 
buffer [750 mM Tris-HCl (pH 8.8), 200 mM (NH4)2SO4, 
0.1% Tween [20], 2.5 mM/l MgCl2, and 1 unit of thermo-
stable Hot Start Taq DNA polymerase (Qiagen, Hilden, 
Germany). The primer sequence and PCR conditions 
are listed in Table 3. MSP-PCR products were analyzed 
by using 2% agarose gel electrophoresis followed 
by ethidium-bromide staining and visualized under 
UV transillumination.
Bisulfite sequencing. MSP-PCR products were 
gel purified (Sigma-Aldrich, St. Louis, Missouri, USA), 
sequenced by using ABI prism Big-Dye terminator 
(Applied Biosystems, Foster City, California, USA) 
and analyzed on an automated DNA sequence ana-
lyzer (3700 ABI Prism, PE Biosystem) to determine the 
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methylation status of CpG sites in the amplified regions. 
Treatment of genomic DNA with sodium bisulfate 
induces deamination of nonmethylated cytosine and 
converts it to uracil and finally to thymidine, but has 
no effect on methylated cytosine. This modification 
allows for differentiation of methylated and nonmethy-
lated CGI in promoter region of tumor suppressor genes 
by MSP-PCR or sequencing. For this purpose, 5 µl of the 
bisulfite-treated DNA amplified by MSP-PCR was run 
on a 2% agarose gel and desired band was gel purified 
using Promega SV gel purification kit (Promega, Madi-
son, Wisconsin, USA) and sent for sequencing using 
the ABI prism Big-Dye Terminator Cycle Sequencing 
Ready Reaction Kit (Applied Biosystems, Foster City, 
CA) on an automated DNA sequence analyzer (3700 ABI 
Prism, PE Biosystem).
Table 3. Primer sequences, annealing temperatures and PCR product size 
used for MSP-PCR and reverse trascription PCR (RT-PCR)
Sequence 5’→3’
Pr
od
uc
t s
ize
An
ne
al
in
g 
te
m
-
pe
ra
tu
re
 (°
C)
Re
f
CASP8 Forward: TAGGGGATTCGGAGATTGCGA 320 50 [24]
methylated Reverse: CGTATATCTACATTCGAAACGA
CASP8 Forward: TAGGGGATTTGGAGATTGTGA 321 53 [24]
nonmethylated Reverse: CCATATATCTACATTCAAAACAA’
TMS1 Forward: CGATTTTGGCGTTTTTCGACGGTT 207 55 [33]
methylated Reverse: CCGCTCACCCCGCTACAACCG C
TMS1 Forward: TTGTTGGAGGGTAATGGATT 272 58 [33]
nonmethylated Reverse: CCCACAAAAATACACCCATA
DAPK Forward: GGATAGTCGGATCGAGTTAACGTC 321 63 [2]
methylated Reverse: CCCTCCCAAACGCCGA
DAPK Forward: GGAGGATAGTTGGATTGAGTTAATGTT 321 63 [2]
nonmethylated Reverse: CAAATCCCTCCCAAACACCAA
CASP8 Forward: AGAGAAGCAGCAGCCTTGAAGG 160 55 [2]
RT-PCR Reverse: AGACAGTATCCCCGAGGTTTGC’
TMS1 Forward: GGACGCCTTGGCCCTCACCG’ 148 65 [33]
RT-PCR Reverse: GGCGCGGCTCCAGAGCCCTG’
DAPK Forward: GATAGAAATGTCCCCAAACCTCG’ 280 55 [2]
RT-PCR Reverse: TCTTCTTTGGATCCTTGACCAGAA’
β-actin Forward: CATGTACGTTGCTATCCAGGC 254 58 [2]
RT-PCR Reverse: CTCCTTAATGTCACGCACGAT
Note: MSP-PCR conditions: 95 °C/5 min followed by 35 cycle 95 °C/45 s; an-
nealing temp./30 s; 72 °C/45 s; 72 °C/10 min; RT-PCR conditions: 94 °C/5 min 
followed by 35 cycle 95 °C/45 s; annealing temp./30 s; 72 °C/45 s; 72 °C/7 min.
RNA isolation. Total RNA was extracted using 
the TRI reagent (Sigma-Aldrich, St. Louis, Missouri, 
USA), according to the manufacturer’s instructions. 
The RNA pellets were reconstituted in DEPC (Sigma-
Aldrich, St. Louis, Missouri, USA) treated water. The 
quality of the RNA samples was determined by elec-
trophoresis through denaturing agarose gels staining 
with ethidium bromide; the 18S and 28S RNA bands 
were visualized under transilluminator. The quality and 
quantity of total RNA was determined spectrophoto-
metrically at 260 and 280 nm.
RT-PCR. Complementary DNAs (cDNAs) were 
reverse transcribed from 1–2 µg of total RNA by use 
of Revert Aid first strand cDNA synthesis kit (Fer-
mentas Life Science, Waltham, Massachusetts, 
USA) according to the manufacturer’s instructions. 
Briefly, 1 µl (0.2 µg/µl) of random hexamer primers was 
added to 1.5 µg of total cellular RNA in a final volume 
of 12 µl followed by addition of supplied 1 µl MuLV 
reverse transcriptase. The reaction mixture was then 
incubated for 1 h at 42 °C, followed by incubation 
at 70 °C for 10 min and subsequently stored at –20 °C.
Gel electrophoresis of the PCR products and 
graphs of melt curve and melt peak indicated that 
target genes could be specifically amplified using 
specific primers. The cDNA concentration was then 
normalized in series of PCR by using β-actin primers 
(see Table 3) and by carefully diluting cDNA until PCR 
products of different samples were similar to each 
other in band intensity using Scion analyzer software. 
The normalized cDNAs were subjected to amplification 
for detection of expression of MTS2 and MTS1 using 
gene specific primers for real-time RT-PCR.
Real-time PCR. Expression of genes was analyzed 
by quantitative real-time PCR using specific primer for 
each gene and SYBR Green Quantitative RT-PCR kit 
(Stratagene, Agilent Technology, USA). All samples 
were analyzed on the Stratagene Real Time Detector. 
β-Actin gene expression was used as invariant con-
trol to normalize input cDNA. Quantitative real-time 
RT-PCR was performed in a reaction volume of 20 µl in-
cluding 1 µl of cDNA. The comparative Ct method was 
used to compute relative expression values.
Statistical analysis. The data were analyzed 
by computing odds ratio (OR) and 95% confidence 
interval (CI) using χ2-test, Fisher exact test and 
multivariate logistic regression with adjustment for 
age as a continuous variable to find out any differ-
ence between cases and healthy controls according 
to age, gender, immunophenotypes, and NCRI risk 
group’s classification. The reported OR can be inter-
preted as age-adjusted estimates of the relative risk 
of developing ALL with methylation of studied genes. 
Analysis of continuous data like age was done by one 
way ANOVA. Statistical analysis was performed using 
SPSS (Version 18, SPSS Inc, Chicago, IL, USA). The 
Mann — Whitney U test was used to assess the sig-
nificance of the difference in mRNA expression level 
of the individual genes and clinical stage. All p values 
< 0.05 were considered statistically significant.
RESULTS
The relevant characteristics of the study subjects 
are summarized in Table 1. In this study, samples 
from 125 patients with ALL and 100 healthy controls 
were collected. The cases and the controls were well 
matched with respect to age, sex and place of living. 
The mean age was 6.50 ± 3.37 years for cases and 
6.40 ± 3.33 years for controls (p = 0.9). 9.6% of pa-
tients were in the age-group of 0–2 years, 43.4% were 
in the age-group of 2–5 years and 56.0% in age group 
of more than 5 years old. The percent of males and 
females among cases and controls were 77.6:77.0 for 
males and 22.4:23.0 for females, respectively.
The cell lineages and NCRI risk groups of ALL 
patients are also presented in Table 1. 94.4% of pa-
tients were diagnosed with B-lineage ALL and 5.6% 
with T-lineage ALL. The patients were stratified into 
two risk groups according to the protocol of National 
Cancer Institute: (i) the high-risk category included 
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patients less than one year or more than 9 years 
old who had a white blood cells count of more than 
50,000/µl at the time of diagnosis (ii) the standard-
risk category included patients aged 1 to 9 years 
who had a white blood cells count of less than 
50,000/µl at the time of diagnosis. All children with 
T-lineage ALL were considered at high risk regard-
less of age and initial white blood cells count. The 
distribution of ALL patients on the basis of NCRI risk 
groups were 82.4% in standard risk group and 17.6% 
in high risk group.
Study of the methylation status of apoptotic 
genes. Bisulfite-treated DNA from all 125 ALL pa-
tients was analyzed for CASP8, TMS1 and DAPK 
promoter hypermethylation by standard MSP-PCR 
technique. Primers for this technique were designed 
to be located within the promoter region associated 
CGI and near the major MSP-PCR analysis of the 
CASP8, TMS1 and DAPK promoters in samples 
using defined nonmethy lated and methylated spe-
cific primers. The frequency of methylation pattern 
of CASP8, TMS1 and DAPK genes has been depicted 
in Table 4. Methylation of CASP8 was found in 3.2% 
of patients. Significant risk of ALL development 
was not observed in patients with hypermethylated 
CASP8 promoter (p > 0.05). Methylation of TMS1 was 
found in 6.4% of patients. Statistically significant 
difference in methylation of TMS1 (p = 0.045) be-
tween patients and controls was observed. Risk 
of ALL increased by 1.64 fold with hypermethylated 
TMS1 promoter (OR = 1.64, 95% CI = 1.26–2.13). 
Methylation of DAPK was found in 13.6% of patients. 
Statistically significant difference in methylation 
of DAPK (p < 0.001) between patients and controls 
was observed. Significant risk of ALL development 
was evident in patients with hypermethy lated DAPK 
promoter (p < 0.01; OR = 1.93, 95% CI = 1.69–2.19) 
(see Table 4).
Table 4. Frequency of methylation with risk of ALL (patients vs healthy control)
Genes Patients  (N = 125), n (%)
Control  
(N = 100), n (%) OR (95% CI) p
Presence of methylation
CASP8 4 (3.2) 0 (0.0) 1.83 (1.62–2.06) 0.13
TMS1 8 (6.4) 1 (1.0) 1.64 (1.26–2.13) 0.045
DAPK 17 (13.6) 0 (0.0) 1.93 (1.69–2.19) 0.001
The frequency of methylation of CASP8, TMS1 and 
DAPK was further analyzed according to selected 
clinicopathological features in ALL patients (Table 5). 
Hypermethylation of CASP8 and DAPK was observed 
in 4.1 and 12.4% and hypermethylation of TMS1 was 
observed in 5.15% of male ALL patients. Statisti-
cally significant difference in methylation of DAPK 
(p < 0.01) between male ALL patients and controls was 
evident. Hypermethylation of CASP8 was observed 
in 4.8% of male patients, methylated promoter was 
not detected in female patients. Statistically signifi-
cant difference in methylation of CASP8 (p = 0.045) 
between male ALL patients and controls was observed 
(OR = 2.08, 95% CI = 1.79–2.4). Hypermethylation 
of TMS1 was detected in 5.15% of male patients and 
10.7% of female patients. Methylation of TMS1 gene 
in association with gender was not statistically signifi-
cant among ALL patients. Hypermethylation of DAPK 
was detected in 12.4% of male patients and 17.9% 
of female patients. Methylation of DAPK gene was 
statistically significant in male and female ALL patients 
as compared to controls. The risk of ALL due to hyper-
methylation of DAPK increased around 1.9 fold in male 
patients and 2.00 fold in female patients (OR = 1.91, 
95% CI = 1.65–2.21 for male and OR = 2.00, 95% CI = 
1.50–2.67 for female patients) (Table 5).
The methylation of CASP8, TMS1 and DAPK in as-
sociation with cell lineage of ALL patients is presented 
in Table 6. Statistically significant relation was not 
evident among these two groups.
Table 6. The frequency and percentage of hypermethylation in promoter 
of genes with B- or T-lineage ALL
Genes B-lineage ALL  (N = 118), n (%)
T-lineage ALL  
(N = 7), n (%) OR (95% CI) p
Presence of methylation
CASP8 4 (3.3) – 1.06 (1.02–1.11) 1
TMS1 6 (5.1) 2 (28.57) 0.80 (0.52–1.17) 0.06
DAPK 16 (13.6) 1 (14.2) 1.00 (0.88–1.13) 1
The frequency of methylation of these genes 
in patients with stratified age groups, namely Age 
< 2 and 2 < Age ≤ 5, Age > 5 are presented in Table 5. 
Hypermethylation of CASP8 was not observed among 
patients with age < 2 years. For age group 2 < Age 
≤ 5 hypermethylation was 2.3% and for Age > 5 it was 
4.28%. Methylation of CASP8 was not statistically sig-
nificant in patients with any of these age groups (p > 
0.05). The percentage of methylated TMS1 was 8.3% 
in patients of Age < 2, 7% in patients of 2 < Age ≤ 5 and 
5.7% in patients of Age > 5. Methylation of TMS1 was 
not statistically significant in patients of all of these 
age groups. The percentage of methylated DAPK was 
16.6% in patients of Age < 2 years, 11.63% in patients 
of 2 < Age ≤ 5, and 14.28% in patients of Age > 5. 
Statistically significant association between methyla-
tion of DAPK gene and development of ALL in patients 
of age > 5 years as compared to healthy controls was 
evident (OR = 1.93, 95% CI = 1.62–2.30) (see Table 5).
The frequency of methylation of CASP8, TMS1 and 
DAPK in relation to NCRI risk is shown in Table 7. Hy-
Table 5. Methylation status of genes with respect to clinicopathological features in childhood ALL patients from North India
CASP8 TMS1 DAPK
Presence 
of methylation OR (95% CI) p
Presence 
of methylation OR (95% CI) p
Presence 
of methylation OR (95% CI) pPatients, 
n (%)
Control, 
n (%)
Patients, 
n (%)
Control, 
n (%)
Patients, 
n (%)
Control, 
n (%)
Male 4 (4.1) – 2.08 (1.79–2.40) 0.05 5 (5.2) 1 (1.2) 1.52 (1.04–2.23) 0.22 12 (12.4) – 1.91 (1.65–2.21) –
Female – – – – 3 (10.7) – 1.92 (1.46–2.52) 0.24 5 (17.9) – 2.00 (1.50–2.67) 0.05
Age < 2 – – – – 1 (8.3) – 2.00 (1.31–3.04) 1 2 (16.6) – 2.10 (1.34–3.29) 0.47
2 < Age < 5 1 (2.3) – 1.79 (1.46–2.18) 1 3 (7.0) 1 (3.0) 1.35 (0.74–2.47) 0.62 5 (11.6) – 1.84 (1.50–2.32) 0.06
Age > 5 3 (4.3) – 1.84 (1.56–2.16) 0.25 4 (5.7) – 1.85 (1.57–2.18) 0.12 10 (14.3) – 1.93 (1.62–2.30) –
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permethylation of CASP8, TMS1 and DAPK was not 
found to be statistically significant in patients of stan-
dard and high risk groups (p > 0.05).
Table 7. The frequency of methylation of genes and NCRI risk groups 
of ALL patients
Genes Standard  (N = 103), n (%)
High  
(N = 22), n (%) OR (95% CI) p
Presence of methylation
CASP8 3 (2.9) 1 (4.5) 0.91 (0.51–1.61) 0.5
TMS1 6 (5.6) 2 (9.0) 0.90 (0.60–1.36) 0.06
DAPK 13 (12.6) 4 (18.1) 0.92 (0.70–1.21) 0.49
Bisulfite sequencing analysis. Treatment of ge-
nomic DNA with sodium bisulfate induces deamina-
tion of nonmethylated cytosine, and conver ting it first 
to uracil and finally to thymidine, but has no effect 
on methylated cytosine. This modification allows 
differentiation of methylated and non-methy lated 
CGI in promoter region of tumor suppressor genes 
by MSP-PCR or sequencing (Fig. 1, 2). The bisulfite 
sequencing analysis of those samples, which were 
hypermethylated in their promoter region of these 
genes as compared with wild type (nonmethylated 
promoter region) revealed conversion of methylated 
cytosine, but not nonmethylated cytosine, which sub-
sequently led to down-regulation of gene expression.
Fig. 1. Result of bisulfite sequence of DAPK
Fig. 2. Result of bisulfite sequence of TMS1
Study on the effect of promoter methylation 
on gene expression by RT-PCR. The differences 
in CASP8, TMS1 and DAPK gene expression in ALL 
patients between methylated and nonmethylated 
stu died genes are presented in Table 8. The trans-
cription of these genes was significantly reduced 
in patients with methylated promoter (p < 0.001) 
in comparison to patients with nonmethylated pro-
moter. Methylation resulted in up to 7.5% down-
regulation in transcription for CASP8, 22.08% for 
TMS1 and 29.5% for DAPK. A significant reduction 
in the mRNA level in relation to patients with selected 
clinicopathological features in ALL patients (p < 
0.05) was observed.
Quantitative RT-PCR. The real time analysis 
of methylated and nonmethylated samples con-
firmed the result of RT-PCR. The hypermethylation 
of promo ter region of CASP8, TMS1 and DAPK 
resulted in their transcriptional down-regulation 
by approximately 0.95-fold, 1.95-fold and 2.85-fold, 
respectively.
Table 8. The impact of promoter hypermethylation on expression genes 
in transcription level among patients of ALL
Genes
Nonmethy-
lated, Mean 
(±SE)
Methylated,
Mean (±SE)
Down-regula-
tion, % p
CASP8 0.748 (±0.01) 0.691 (±0.01) 7.58 0.03
TMS1 0.801 (±0.02) 0.667 (±0.01) 22.08 0.001
DAPK 0.866 (±0.02) 0.610 (±0.05) 29.50 0.001
DISCUSSION
The present study was carried out to investigate 
epigenetic changes like promoter hypermethylation 
of tumor suppressor genes like CASP8, TMS1 and 
DAPK with respect to different clinicopathological 
factors in childhood ALL within the population under 
study. CASP8 encodes an initiator caspase that plays 
an important role in the Fas-Fas ligand pathway [22, 
23]. Alterations of these genes have been described 
in several neoplasia, like neuroblastoma and medul-
loblastoma [19, 24]. Harada et al. [25] observed 
frequent methylation of CASP8 in pediatric rhabdo-
myosarcomas, medulloblastomas, retinoblastomas 
and neuroblastomas. The frequency of hypermeth-
ylated CASP8 was found to be low in Wilms tumors 
and they could not observe any aberrant methylation 
of CASP8 in hepatoblastomas, acute leukemias, os-
teosarcomas and ganglioneuromas and also in healthy 
controls.
Harada et al. [25] reported the absence of methyla-
tion of CASP8 in Ewing sarcoma tumors. In contrast, 
Fulda et al. [26] showed around 65% methylation 
of CASP8 in Ewing sarcoma. CASP8 as reported 
by other research group was methylated and inacti-
vated in neuroendocrine lung carcinomas (small cell 
and bronchial carcinoids) but not in non-small cell 
carcinomas [27]. Also, hypermethylation-mediated 
down-regulation of caspase-8 has been reported 
by Wu et al. [28]. Structurally, the promoter region 
of CASP8 has binding sites for p53, NF-κB, AP-1, 
SP-1, IRF-1, and Ets-like transcription factors [29]. 
Therefore, caspase-8 functions both as a pivotal 
molecule for death-receptor-induced apoptosis 
and as a selective signal transducer, such as for 
NF-κβ activation [30]. Absence or down-regulation 
of caspase-8 could cause resistance to apoptosis 
and correlated with unfavorable disease outcome, 
such as in childhood medulloblastoma and neuro-
blastoma [31, 32].
Till now, very few investigations of hematologi-
cal malignancies have focused on CASP8 promoter 
hypermethylation. As caspase-8 mRNA was down-
regulated or silenced in the other malignancies, the 
possibility of promoter hypermethylation induced cas-
pase-8 transcriptional silencing was investigated in the 
present study. It was observed that the distribution 
pattern of methylation was different among male ALL 
patients as compared with healthy controls (p < 0.05). 
These results revealed significant trend towards in-
creasing risk of ALL with methylation of CASP8 in male 
62 Experimental Oncology 39, 57–64, 2017 (March)
patient samples as compared with healthy controls. 
To the best of our knowledge, there are no reports 
on correlation of CASP8 hypermethylation in childhood 
ALL. Overall, the hypermethylation of CASP8 in as-
sociation with age of patient did not show any impact 
in development and increasing risk of childhood ALL 
in our population under study. The cell lineage of ALL 
does not have any impact on methylation pattern 
of CASP8 in our population under study (p > 0.05). 
The bisulfite sequencing results confirm the MSP-PCR 
data. Regarding the distribution pattern of methylated 
CGI, no significant pattern was found in this study. 
The low level of down-regulation of mRNA expression 
of caspase-8 (7.58%) was due to aberrant promoter 
methylation in childhood ALL. In the quantitative study 
of transcription with real time PCR, 0.95-fold down-
regulation of caspase-8 was observed.
TMS1 is commonly silenced by methylation in hu-
man cancer cells. TMS1 down-regulation is induced 
by overexpression of human DNA methyltransfe-
rase-1 [12]. Methylation pattern of TMS1 and its effect 
on the mRNA expression of TMS1 in so many cancer 
cell lines especially, epithelial cancer cell lines have 
been shown by many research groups [12, 33]. Meth-
ylation of the promoter region of TMS1/ASC has been 
reported in small cell lung cancer and non-small cell 
lung cancer [34], glioblastoma [35], ovarian, colorec-
tal and prostate cancer [33, 36, 37]. In the present 
study, hypermethylation of TMS1 was found in 8 out 
of 125 (6.5%) ALL patients, which was marginally sig-
nificant. Our result was contrary to the report of Roman-
Gomez et al. [38] in ALL patients. Our data revealed 
no significant trend towards increasing risk of ALL with 
methylation of TMS1 gene in both genders among the 
patient samples as compared with healthy controls 
(p > 0.05). The hypermethylation of TMS1 in associa-
tion with the age of patients did not show any impact 
in deve lopment of childhood ALL in the north Indian 
population (p > 0.05). This finding was in consistency 
with the report of Roman-Gomez et al. [38]. Our data 
indicated that cell lineage of ALL does not have any 
impact on methylation pattern of TMS1 in the popula-
tion under study (p > 0.05). It might be assumed that 
the methylation pattern of TMS1 in standard risk group 
and high risk group could not be used as a potential 
biomarker in risk of ALL. Interestingly, 22.8% down-
regulation of TMS1 mRNA expression was observed 
in our population under study. In the quantitative 
study of transcription using real time PCR, 1.95-fold 
down-regulation of TMS1 was observed. The analysis 
of the results of semiquantitative and quantitative 
PCR showed the effect of hypermethylated promoter 
in down-regulation of TMS1. Furthermore, it is also 
involved in an intrinsic p53-dependent apoptotic 
checkpoint [39].
DAPK has been shown to be involved in normal cell 
differentiation and loss of the DAPK gene expression 
was reported in some malignancies as well as cance-
rous cell lines [8, 9]. Clinically, loss of DAPK expres-
sion, and therefore, absence of apoptosis in tumor 
cells could be considered as a biomarker of disease 
progression [40]. The promoter region of the DAPK 
contains a CGI that has been shown to be hypermethy-
lated in solid tumors like squamous cell carcinoma 
of neck in 67% in German population.
Apoptosis is one of the hallmarks of cancer [41]. 
DAPK is an important pro-apoptotic gene inactivated 
in many tumor types. Several studies of DAPK inacti-
vation in lung cancers have been published [42–45] 
in which hypermethylation of the DAPK promoter was 
shown to be associated with loss of expression [45–
47]. Although limited number of reports is available, 
attempts were made to find out the profile of DAPK 
promoter hypermethylation in childhood ALL in the 
present study. The results were shown to be completely 
in contrast to each other in different ethnic groups. 
It has been reported that DAPK promoter was ap-
proximately 17% hypermethylated in adult and ~10% 
in childhood ALL in Hispanic children [38]. In contrast, 
DAPK promoter was not hypermethylated in T-ALL 
samples of Dutch population [45]. Also, it has been 
reported from Japanese childhood ALL that in none 
of the samples DAPK was hypermethylated [48]. Aber-
rant DAPK transcription has been reported in leukemia 
and lymphoma [38]. It was demonstrated that the 
down-regulation of expression of DAPK gene resulting 
from aberrant gene promoter hypermethylation was 
associated with disease progression in hematological 
malignancies [49, 50].
In present work, an attempt has been made to study 
the involvement of DAPK in clinicopathological process 
of ALL. As DAPK transcription was down-regulated 
in some of the ALL samples analyzed in this study, 
the possibility of promoter hypermethylation induced 
DAPK transcriptional down-regulation was therefore 
investigated. It was observed that hypermethylation 
of DAPK was present in 17 out of 125 (13.6%) ALL 
patients. This is in consistency with the other reports 
of Roman-Gomez et al. and Chim et al. [38, 51]. 
Significant effect of DAPK hypermethy lation was ob-
served in their population of study. The hypermethy-
lation of DAPK in both the genders increased the risk 
of childhood ALL, but no significant trend towards 
risk of ALL was observed in our population under 
study. No significant difference in aberrant methyla-
tion of DAPK promoter could be observed in all age 
groups (p > 0.05). Also we assume that the methylation 
pattern of DAPK in standard risk group and high risk 
group did not have any impact towards the increasing 
risk of ALL in studied population. Unlike other groups 
which in their reports did not mention percentage 
of down-regulation for DAPK it was tried to find out the 
percentage of down-regulation of hypermethylated 
promoter of DAPK for each variable of study separately 
and this was done on the basis of statistical calcula-
tion to find out the correlation between each variable 
and expression of DAPK gene. In the present study, 
19% down-regulation of DAPK was observed. In the 
quantitative study of transcription with real time PCR, 
2.85-fold down-regulation of DAPK was observed. 
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The analysis of result of semiquantitative and quanti-
tative RT-PCR showed the effect of hypermethylated 
promoter in down-regulation of DAPK. It was demon-
strated that the down-regulation of mRNA expression 
of DAPK by its aberrant promoter hypermethylation 
could be considered as one of the factors affecting 
the DAPK transcription.
In this study, we tried to detect the relation among 
the apoptotic genes which have been selected for 
this study with respect to variables. In our set of ALL 
samples, the most common situation is the simultane-
ous absence of methylation in both promoters but after 
this, the possible scenarios (CASP8 methylated alone, 
TMS1 methylated alone, DAPK methylated alone, 
CASP8, TMS1 both methylated or CASP8, DAPK both 
methylated and CASP8 and DAPK both methylated) 
are similarly represented. In ALL, hypermethylation 
in the promoter of these genes was an independent 
event. In the present study, an attempt was made 
to detect the relation among the apoptotic genes which 
have been selected for this study with respect to vari-
able of study of interaction between CASP8 and TMS1. 
Association in the risk of ALL for each variable of study 
even when the both the genes were methylated was 
not detected. Also in interaction between CASP8 and 
DAPK, no association was found even when both the 
genes were methylated simultaneously. In the study 
of interaction between DAPK and TMS1 no association 
was observed. Significant correlation in interaction 
among this gene family was not observed. From these 
results it has been deduced that the hypermethylation 
in promoter region of these genes was independent 
to each other. The present findings need to be ex-
tended to a larger series.
To sum up, our results showed no significant role 
of caspase-8 as a tumor suppressor gene in patho-
genesis of ALL in north Indian population. Aberrant 
promoter hypermethylation of DAPK and TMS1 as tu-
mor suppressor genes may support the role in patho-
genesis and increase the risk of ALL in north Indian 
population. The methylation status of the DAPK and 
TMS1 genes might be considered as a predictive factor 
in the clinical outcome of ALL.
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